Lab Reference Library / Serum Tryptase Inflammation and Immune

Serum Tryptase

Q: What is a normal tryptase level?

The standard upper limit for baseline serum tryptase is 11.4 ng/mL. Functional medicine considers levels below 8.0 ng/mL as optimal baseline. A baseline tryptase persistently above 20 ng/mL raises strong suspicion for systemic mastocytosis and warrants hematology evaluation including bone marrow biopsy. For MCAS evaluation, the diagnostic criterion is an acute tryptase rise of at least 20% plus 2 ng/mL above the individual's established baseline, drawn within 1 to 4 hours of a symptomatic episode.

Q: What does elevated tryptase mean?

Elevated baseline tryptase indicates increased mast cell number (mastocytosis) or increased constitutive mast cell activation. Persistently elevated tryptase above 20 ng/mL is the WHO minor criterion for systemic mastocytosis. Moderately elevated baseline tryptase (11.4 to 20 ng/mL) can reflect hereditary alpha-tryptasemia (a genetic duplication of the alpha-tryptase gene affecting approximately 5% of the population), chronic mast cell activation, myeloid neoplasms, or renal insufficiency (reduced tryptase clearance). Acute elevation during a symptomatic episode confirms mast cell degranulation.

Q: Can tryptase be normal in MCAS?

Yes. This is one of the most important clinical points about tryptase in MCAS evaluation. Many patients with MCAS have normal baseline tryptase because their mast cell number is normal; the problem is inappropriate activation, not excessive number. The diagnostic utility of tryptase in MCAS depends on capturing an acute level during or within 1 to 4 hours of a symptomatic episode and comparing it to the established baseline. If acute tryptase rises 20% plus 2 ng/mL above baseline, mast cell degranulation is confirmed. Other mediators (histamine, prostaglandin D2, N-methylhistamine) may be elevated when tryptase is normal.

Q: When should tryptase be tested?

Baseline tryptase should be drawn in patients with suspected MCAS (unexplained flushing, urticaria, GI symptoms, tachycardia, food intolerances, exercise intolerance with mast cell features), history of anaphylaxis (to evaluate for underlying mastocytosis), unexplained recurrent allergic-type reactions, and as part of the evaluation for Ehlers-Danlos syndrome (EDS patients have a higher prevalence of MCAS). Acute tryptase should be drawn within 1 to 4 hours of a symptomatic episode (anaphylaxis, severe flushing, unexplained hypotension) and compared to the baseline.

Q: What is hereditary alpha-tryptasemia?

Hereditary alpha-tryptasemia (HaT) is a genetic condition caused by duplications of the TPSAB1 gene encoding alpha-tryptase. It affects approximately 5 to 6% of the general population and produces a persistently elevated baseline tryptase (typically 8 to 25 ng/mL) without systemic mastocytosis. HaT is associated with a higher prevalence of symptoms that overlap with MCAS: flushing, GI dysmotility, chronic pain, autonomic dysfunction, and connective tissue laxity. HaT is diagnosed by genetic testing (TPSAB1 copy number analysis) and is important to distinguish from mastocytosis because the clinical management differs.

Total Tryptase · Mature Tryptase · Mast Cell Tryptase

Reference range, optimal functional medicine interpretation, and why tryptase is the primary blood marker of mast cell burden and activation. Baseline tryptase reflects total mast cell number, while acute tryptase (drawn during a symptomatic episode) confirms mast cell degranulation. Essential for evaluating mast cell activation syndrome (MCAS), mastocytosis, and anaphylaxis.

Mast Cell MarkerMCAS Evaluation

Standard RangeBelow 11.4 ng/mL

FM OptimalBelow 8.0 ng/mL

Fasting RequiredNo

Unitsng/mL

← Back to Lab Reference Library

Category: Inflammation and Immune | Also known as: Total Tryptase, Mature Tryptase, Mast Cell Tryptase | Sample: Serum (fasting not required; acute sample within 1 to 4 hours of episode)

1. What This Test Measures

Serum tryptase is a serine protease enzyme stored in the secretory granules of mast cells. Mast cells are tissue-resident immune cells positioned at the interface between the body and the environment: skin, airways, gut mucosa, and blood vessel walls. When mast cells degranulate (release their granule contents), tryptase is released alongside histamine, prostaglandins, leukotrienes, heparin, and cytokines. Tryptase is the most clinically useful mast cell mediator to measure in blood because it is stable, has a predictable half-life (approximately 2 hours), and is specific to mast cells (unlike histamine, which is also produced by basophils and has a half-life of only minutes).

Total serum tryptase includes two forms: alpha-tryptase (pro-tryptase), which is constitutively secreted by mast cells at a rate proportional to the total mast cell number in the body, and beta-tryptase (mature tryptase), which is stored in granules and released during degranulation. A baseline tryptase (drawn when the patient is asymptomatic) primarily reflects alpha-tryptase and therefore reflects the total mast cell burden. An acute tryptase (drawn within 1 to 4 hours of a symptomatic episode) reflects both alpha and beta tryptase, and the increase above baseline confirms that mast cell degranulation occurred.

The diagnostic criterion for acute mast cell activation: acute tryptase must rise to at least 20% above the individual's baseline plus 2 ng/mL (the "20% + 2" rule). For example, a patient with a baseline tryptase of 6.0 ng/mL must have an acute tryptase of at least 9.2 ng/mL (6.0 x 1.2 + 2 = 9.2) to confirm mast cell degranulation. This formula accounts for the fact that patients with higher baseline tryptase need a proportionally larger absolute increase to confirm activation.

2. Why This Test Matters

Mast cell activation syndrome (MCAS) evaluation: MCAS is a condition in which mast cells degranulate excessively in response to triggers that would not activate mast cells in healthy individuals. Tryptase is one of the diagnostic criteria: an acute rise above baseline (20% + 2 rule) confirms mast cell mediator release. MCAS produces multi-system symptoms including flushing, urticaria, GI dysfunction, tachycardia, and exercise intolerance
Systemic mastocytosis screening: persistently elevated baseline tryptase above 20 ng/mL is a WHO minor diagnostic criterion for systemic mastocytosis (SM), a myeloproliferative neoplasm characterized by abnormal mast cell accumulation in bone marrow and other tissues
Anaphylaxis confirmation: acute tryptase drawn within 1 to 4 hours of suspected anaphylaxis confirms that the reaction involved mast cell degranulation. This distinguishes anaphylaxis from vasovagal reactions, panic attacks, and other anaphylaxis mimics
Hereditary alpha-tryptasemia (HaT) identification: approximately 5 to 6% of the general population carries extra copies of the TPSAB1 gene, producing constitutively elevated baseline tryptase (typically 8 to 25 ng/mL) without mastocytosis. HaT is associated with symptoms overlapping MCAS, dysautonomia, and connective tissue laxity
Post-anaphylaxis risk stratification: patients with elevated baseline tryptase who have experienced anaphylaxis are at higher risk of future severe reactions, particularly during venom immunotherapy or perioperative settings
Treatment response monitoring: in patients with confirmed MCAS or mastocytosis, serial tryptase measurements track disease activity and response to mast cell stabilization therapy

3. Standard Lab Reference Range

Tryptase Level	Classification	Clinical Notes
Below 11.4 ng/mL	Normal	Standard upper limit; does not rule out MCAS if baseline is established
11.4 to 20 ng/mL	Elevated	Evaluate for HaT (genetic), chronic mast cell activation, renal insufficiency, myeloid neoplasm
Above 20 ng/mL	Significantly elevated	WHO minor criterion for systemic mastocytosis; hematology evaluation indicated
Acute rise: 20% + 2	Activation confirmed	Confirms mast cell degranulation when acute exceeds baseline by this formula

4. Optimal Functional Medicine Range

Tryptase Level	Functional Interpretation
Below 5.0 ng/mL	Low normal: minimal mast cell burden; unlikely mast cell pathology
5.0 to 8.0 ng/mL	Optimal baseline: normal mast cell number; adequate reference for acute comparison
8.0 to 11.4 ng/mL	Upper normal: evaluate for HaT if persistent; establish as baseline for acute comparison
11.4 to 20 ng/mL	Elevated: distinguish HaT (genetic testing), chronic mast cell activation, or secondary causes
Above 20 ng/mL	Mastocytosis concern: bone marrow biopsy and hematology referral indicated

The baseline is the key: a single tryptase value without context is incomplete information. Every patient in whom mast cell disease is suspected needs an established baseline tryptase (drawn when asymptomatic) so that acute values drawn during episodes can be compared. The 20% + 2 formula requires a known baseline. Without it, acute tryptase cannot be interpreted properly.

5. Tryptase in the Complete Mast Cell Panel

Marker	What It Adds	When to Draw
Serum Tryptase (this page)	Mast cell burden (baseline) and degranulation (acute)	Baseline: any time; Acute: within 1 to 4 hr of episode
Plasma Histamine	Immediate mast cell mediator; very short half-life (minutes)	Within 15 to 60 min of episode; on ice
24-hr Urine N-methylhistamine	Stable histamine metabolite; captures daily histamine production	24-hour collection; refrigerated
Prostaglandin D2 (or 11-beta-PGF2alpha)	Mast cell-specific prostaglandin; not produced by basophils	Spot urine or 24-hr collection
hs-CRP	Systemic inflammation context; mast cells contribute to CRP elevation	Any time
IgE (total)	Allergic sensitization status; guides allergy vs MCAS distinction	Any time

6. Symptoms Associated With Mast Cell Activation

Skin and Vascular

Flushing (face, neck, upper chest; episodic)
Urticaria (hives) without identifiable allergen
Angioedema (swelling of lips, eyes, or throat)
Dermatographism (skin writing; wheal response to scratching)
Pruritus (itching) without rash
Tachycardia (rapid heart rate, palpitations)
Hypotension or presyncope during episodes

GI, Respiratory, and Neurological

Abdominal pain, cramping, diarrhea (mast cell mediator effects on gut)
Nausea and reflux symptoms
New food intolerances (especially histamine-containing foods)
Wheezing, dyspnea, throat tightness
Brain fog and cognitive impairment during episodes
Headaches (histamine-mediated vasodilation)
Exercise intolerance with mast cell activation features
Bone pain (if mastocytosis with marrow involvement)

7. What Causes Elevated Tryptase

Systemic mastocytosis: clonal proliferation of abnormal mast cells, typically with KIT D816V mutation. Baseline tryptase persistently above 20 ng/mL. Requires bone marrow biopsy for diagnosis. WHO diagnostic criteria include tryptase above 20 as a minor criterion alongside multifocal mast cell aggregates, aberrant CD25 expression, and KIT mutation
Hereditary alpha-tryptasemia (HaT): genetic duplication of the TPSAB1 gene producing extra alpha-tryptase. Affects approximately 5 to 6% of the population. Baseline tryptase typically 8 to 25 ng/mL. Diagnosed by TPSAB1 copy number analysis. Associated with MCAS-like symptoms, dysautonomia, GI dysmotility, and connective tissue laxity
Acute mast cell activation: MCAS episodes produce transient tryptase elevation (acute rise above baseline by 20% + 2). Baseline may be normal between episodes in many MCAS patients
Anaphylaxis: severe mast cell degranulation during anaphylaxis produces the highest acute tryptase elevations (often above 20 to 50 ng/mL), typically peaking at 60 to 90 minutes and normalizing within 6 to 12 hours
Myeloid neoplasms: acute myeloid leukemia (AML), myelodysplastic syndromes, and other myeloproliferative disorders can produce elevated tryptase because mast cells are derived from the myeloid lineage
Renal insufficiency: reduced renal clearance of tryptase produces elevated levels independent of mast cell disease. Check renal function when interpreting unexplained tryptase elevation
Chronic inflammation: persistent inflammatory states can chronically activate mast cells, producing mildly elevated baseline tryptase without meeting formal MCAS or mastocytosis criteria

8. How to Stabilize Mast Cells and Reduce Activation

Mast Cell Stabilization

Quercetin (500mg twice daily): a natural flavonoid mast cell stabilizer that inhibits mast cell degranulation by stabilizing the cell membrane. The most widely used natural mast cell stabilizer in functional medicine
Cromolyn sodium (oral or nebulized): a pharmaceutical mast cell stabilizer that prevents degranulation. Oral cromolyn (Gastrocrom) is used for GI mast cell symptoms. Nebulized cromolyn for respiratory symptoms
Luteolin (100 to 200mg daily): another flavonoid with mast cell stabilizing properties, often combined with quercetin for synergistic effect
Vitamin C (1000 to 2000mg daily in divided doses): promotes histamine degradation through diamine oxidase (DAO) support and provides mast cell membrane stabilization

Mediator Blockade

H1 antihistamine (cetirizine 10mg twice daily): blocks histamine at H1 receptors (skin, respiratory, CNS). Non-sedating second-generation agents preferred. Twice-daily dosing for continuous coverage
H2 antihistamine (famotidine 20mg twice daily): blocks histamine at H2 receptors (GI tract, cardiac). Reduces gastric acid hypersecretion and GI symptoms from mast cell mediators
Leukotriene receptor antagonist (montelukast 10mg daily): blocks leukotriene-mediated bronchoconstriction, nasal congestion, and inflammatory signaling from mast cell-derived leukotrienes
Aspirin (81 to 325mg daily, if tolerated): inhibits prostaglandin D2 production. Note: some MCAS patients are aspirin-sensitive; start low dose with observation

Dietary and Trigger Management

Low-histamine diet: eliminate fermented foods (sauerkraut, kimchi, kombucha, aged cheese, wine, beer), cured meats, leftover proteins (histamine increases as protein sits), vinegar, and high-histamine fruits (citrus, strawberries, tomatoes). This is typically a 4 to 8 week elimination trial
DAO supplementation (before meals): diamine oxidase enzyme supplement taken 15 minutes before meals to break down dietary histamine in the gut before absorption
Trigger identification and avoidance: common MCAS triggers include temperature changes, physical exertion, stress, medications (NSAIDs, opioids, contrast dye), fragrances, and certain food additives
Gut restoration: intestinal barrier repair reduces the translocation of food-derived histamine and other immunogenic compounds that trigger mast cells
Stress management: corticotropin-releasing hormone (CRH) directly activates mast cells; stress reduction reduces this activation pathway

9. Related Lab Tests

hs-CRPSystemic Inflammation Context

→

CortisolStress Axis; CRH Activates Mast Cells

→

Vitamin DImmune Modulation; Supports Mast Cell Regulation

→

Fasting InsulinMetabolic Context for Multi-System Symptoms

→

ZincDAO Cofactor; Supports Histamine Degradation

→

FerritinElevated Ferritin in Mastocytosis and HaT

→

10. When Testing Is Recommended

Suspected MCAS: patients with episodic multi-system symptoms (flushing, urticaria, GI dysfunction, tachycardia, exercise intolerance) without identifiable allergic trigger
History of anaphylaxis: baseline tryptase identifies patients with elevated mast cell burden at higher risk of future severe reactions
Acute anaphylaxis confirmation: draw within 1 to 4 hours of suspected anaphylactic episode and compare to established baseline
Ehlers-Danlos syndrome evaluation: EDS patients have higher prevalence of MCAS and benefit from mast cell screening
Unexplained recurrent allergic-type reactions without identifiable allergen on testing
Persistent elevation on prior testing: evaluate for hereditary alpha-tryptasemia (TPSAB1 genetic testing), systemic mastocytosis (bone marrow biopsy if above 20 ng/mL), or secondary causes
Monitoring treatment response in confirmed MCAS or mastocytosis: serial tryptase tracks disease activity
Draw alongside plasma histamine (within 15 to 60 min of episode, on ice), 24-hour urine N-methylhistamine, and prostaglandin D2 metabolites for comprehensive mast cell mediator assessment

11. Clinical Perspective

Clinical Perspective

The most common mistake I see with tryptase is drawing it once, finding it normal, and concluding that mast cells are not the problem. A normal baseline tryptase does not rule out MCAS. Many MCAS patients have a normal mast cell number; their problem is inappropriate activation, not excessive number. The diagnostic power of tryptase is in the comparison between baseline and acute. You need both. I instruct every patient in whom I suspect MCAS to have their baseline tryptase drawn when they are feeling well, and then to go to the lab or emergency department during their next episode and request an acute tryptase within 1 to 4 hours. If the acute rises by 20% plus 2 above baseline, we have confirmed mast cell degranulation. If tryptase does not rise, we check the other mediators: urine N-methylhistamine, prostaglandin D2, and plasma histamine. The mast cell mediator panel is like a net; tryptase alone catches some patients, but the full panel catches most of them.

Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma

12. Frequently Asked Questions

What is a normal tryptase level?

Standard upper limit: 11.4 ng/mL. Functional medicine optimal baseline: below 8.0 ng/mL. Above 20 ng/mL persistently raises concern for systemic mastocytosis (WHO minor criterion). For MCAS diagnosis, the criterion is acute tryptase rising at least 20% plus 2 ng/mL above the individual's established baseline, drawn within 1 to 4 hours of symptoms.

What does elevated tryptase mean?

Elevated baseline: increased mast cell number (mastocytosis), hereditary alpha-tryptasemia (genetic, approximately 5 to 6% of population), chronic mast cell activation, myeloid neoplasm, or renal insufficiency. Elevated acute (above baseline by 20% + 2): confirms mast cell degranulation during that episode. Distinction between causes requires clinical context and additional testing.

Can tryptase be normal in MCAS?

Yes. Many MCAS patients have normal baseline tryptase because the mast cell number is normal; the problem is inappropriate activation. Diagnostic utility depends on capturing an acute level during symptoms and comparing to baseline. Other mediators (histamine, prostaglandin D2, N-methylhistamine) may be elevated when tryptase is normal. The full mast cell mediator panel is more sensitive than tryptase alone.

When should tryptase be tested?

Suspected MCAS (episodic multi-system symptoms without clear allergen), history of anaphylaxis (risk stratification), acute anaphylaxis confirmation (draw within 1 to 4 hours), Ehlers-Danlos syndrome evaluation (higher MCAS prevalence), unexplained recurrent allergic reactions, and monitoring treatment response in confirmed mast cell disease.

What is hereditary alpha-tryptasemia?

Genetic duplication of the TPSAB1 gene encoding alpha-tryptase. Affects approximately 5 to 6% of the population. Produces persistently elevated baseline tryptase (typically 8 to 25 ng/mL) without mastocytosis. Associated with MCAS-like symptoms, dysautonomia, GI dysmotility, and connective tissue laxity. Diagnosed by TPSAB1 copy number genetic testing. Management differs from mastocytosis.

Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.

Tryptase tells you whether mast cells are the problem. But you need the baseline to read the story.

Comprehensive mast cell evaluation includes baseline tryptase, acute mediator testing, and identification of triggers driving activation. Distinguish MCAS from mastocytosis from hereditary alpha-tryptasemia with objective data. Schedule a consultation at The Lamkin Clinic.

Schedule a Consultation

Medical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Mast cell disease evaluation requires clinical context including symptom history, mediator testing, and in some cases bone marrow biopsy. Lab interpretation should always be performed by a qualified healthcare provider. Schedule a consultation to discuss your specific results with Brian Lamkin, DO.